NCT07620431Not yet recruiting
Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing Sarcoma
An Observational Study on the Safety and Efficacy of Neoadjuvant Concurrent Chemoradiotherapy Sequential Surgery for High-Risk Localized Ewing Sarcoma
Source: ClinicalTrials.gov · Last updated 2 Jun 2026
Brief summary (registry, in English)
This is a single-center, single-arm, prospective observational study to evaluate the long-term local control rate, safety, and efficacy of preoperative neoadjuvant radiotherapy (36-45 Gy) followed by sequential radical surgery and postoperative chemotherapy in patients with high-risk, resectable localized Ewing sarcoma.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 55 (estimated)
- First submitted
- 15 May 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Childhood cancers, Sarcoma
- NCT number
- NCT07620431
What you commit to
- Study type: Observational
- Planned participants: 55
- From 1 Jun 2026 to the primary completion date, 1 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- No opportunity for surgical resection after neoadjuvant chemotherapy.
- Extensive metastasis with no indication for local surgical resection.
- Uncontrolled concurrent medical conditions.
- Prior radiotherapy to the surgical site during front-line treatment.
Other illness
- History of other malignant tumors within the past 5 years.
- Inability to cooperate with preoperative neoadjuvant radiotherapy (e.g., due to psychiatric factors).
- Any condition that, in the investigator's judgment, might harm the patient or prevent compliance with study requirements.
Who the study is looking for
- The subject or their legal representative signs the written informed consent prior to enrollment.
- Age \<= 55 years old.
- Histologically confirmed Ewing sarcoma, with FET family (including EWSR1 or FUS) gene rearrangement confirmed by FISH or NGS. Clear FET-non ETS fusion cases are excluded.
- Deemed difficult to achieve a satisfactory surgical margin by 2 or more senior musculoskeletal oncologists.
- ECOG Performance Status: 0-1.
- Expected life expectancy \>= 3 months.
- Women of childbearing potential must have a negative pregnancy test within 1 week prior to enrollment and agree to use contraception; male subjects must agree to use contraception or have undergone surgical sterilization during the study.
Age in the registry: 12 months to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital, Beijing, Beijing 100044 Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.